TABLE 1.
Clinical characteristics of the lung adenocarcinoma patients (TCGA).
| Characteristics | Total | Low expression | High expression | P-value |
| N (%) | N (%) | N (%) | ||
| T stage | 0.199 | |||
| T1 | 175 (32.9%) | 97 (18.2%) | 78 (14.7%) | |
| T2 | 289 (54.3%) | 140 (26.3%) | 149 (28%) | |
| T3 | 49 (9.2%) | 21 (3.9%) | 28 (5.3%) | |
| T4 | 19 (3.6%) | 7 (1.3%) | 12 (2.3%) | |
| N stage | 0.006** | |||
| N0 | 348 (67.0%) | 188 (36.2%) | 160 (30.8%) | |
| N1 | 95 (18.3%) | 39 (7.5%) | 56 (10.8%) | |
| N2 | 74 (14.3%) | 28 (5.4%) | 46 (8.9%) | |
| N3 | 2 (0.4%) | 0 (0%) | 2 (0.4%) | |
| M stage | 1.000 | |||
| M0 | 361 (93.5%) | 184 (47.7%) | 177 (45.9%) | |
| M1 | 25 (6.5%) | 13 (3.4%) | 12 (3.1%) | |
| Pathologic stage | 0.002** | |||
| Stage I | 294 (55.8%) | 165 (31.3%) | 129 (24.5%) | |
| Stage II | 123 (23.3%) | 50 (9.5%) | 73 (13.9%) | |
| Stage III | 84 (16.0%) | 31 (5.9%) | 53 (10.1%) | |
| Stage IV | 26 (4.9%) | 14 (2.7%) | 12 (2.3%) | |
| Gender | 0.005** | |||
| Female | 286 (53.5) | 126 (23.6%) | 160 (29.9%) | |
| Male | 249 (46.5) | 141 (26.4%) | 108 (20.2%) | |
| Age | 0.134 | |||
| < = 65 | 255(49.4) | 118 (22.9%) | 137 (26.6%) | |
| >65 | 261(50.6) | 139 (26.9%) | 122 (23.6%) | |
| Smoker | 0.327 | |||
| No | 75(14.4) | 33 (6.3%) | 42 (8.1%) | |
| Yes | 446(85.6) | 227 (43.6%) | 219 (42%) | |
| Anatomic neoplasm subdivision | 1.000 | |||
| Left | 205(39.4) | 102 (19.6%) | 103 (19.8%) | |
| Right | 315 (60.6) | 156 (30%) | 159 (30.6%) | |
| Anatomic neoplasm subdivision 2 | 0.671 | |||
| Central lung | 62 (32.8) | 27 (14.3%) | 35 (18.5%) | |
| Peripheral lung | 127 (67.2) | 61 (32.3%) | 66 (34.9%) | |
**P < 0.01.